Airway Physiology Group, Woolcock Institute of Medical Research, Glebe, Australia.
J Allergy Clin Immunol. 2012 Jul;130(1):61-8. doi: 10.1016/j.jaci.2012.02.015. Epub 2012 Mar 27.
Asthma guidelines recommend inhaled corticosteroid (ICS) dose titration for patients on the basis of an assessment of current asthma control. However, the physiological determinants of asthma symptom control are poorly understood and spirometry is a poor predictor of symptomatic response.
To determine the role of small airway measurements in predicting the symptom response following ICS dose titration.
Adult asthmatic patients had the Asthma Control Questionnaire (ACQ) scores and lung function measured at baseline and after 8 weeks. Tests included spirometry, plethysmography, sputum cell count, exhaled nitric oxide, airway hyperresponsiveness to mannitol, respiratory system mechanics using the forced oscillation technique, and ventilation heterogeneity using the multiple breath nitrogen washout. The parameters ventilation heterogeneity in convection-dependent airways and ventilation heterogeneity in diffusion-dependent airways were derived as measures of ventilation heterogeneity in the small airways. The dose of ICS was doubled if the ACQ score was greater than or equal to 1.5 (uptitration) and quartered if the ACQ score was less than 1.5 (downtitration). The relationships between baseline physiological parameters and the change in the symptom-only 5-item ACQ (deltaACQ-5) were examined by using Spearman correlations, forward stepwise linear regressions, and receiver operator curve analyses.
ICS dose uptitration (n= 20) improved ACQ-5 scores (1.76 to 1.16; P= .04). Baseline fraction of exhaled nitric oxide (r= -0.55; P= .01) and ventilation heterogeneity in convection-dependent airways (r= -0.64; P= .002) correlated with deltaACQ-5, but ventilation heterogeneity in convection-dependent airways was the only independent predictor (r(2) = 0.34; P = 0.007). ICS dose downtitration (n= 41) worsened ACQ-5 scores (0.46 to 0.80; P< .001), with 29% of the patients having a deltaACQ-5 of greater than 0.5. Only baseline ventilation heterogeneity in diffusion-dependent airways correlated with deltaACQ-5 (r= 0.40; P= .009) and identified subjects with deltaACQ-5 of greater than 0.5 (receiver operator curve area under the curve= 0.78; P= .0003).
Ventilation heterogeneity predicts symptomatic responses to ICS dose titration. Worse small airways function predicts symptomatic improvement to ICS dose uptitration and loss of symptom control during downtitration.
哮喘指南建议根据当前哮喘控制情况评估,对吸入性皮质类固醇(ICS)剂量进行滴定。然而,哮喘症状控制的生理决定因素仍知之甚少,且肺量计对症状反应的预测效果不佳。
确定小气道测量在预测 ICS 剂量滴定后症状反应中的作用。
成年哮喘患者在基线和 8 周后测量哮喘控制问卷(ACQ)评分和肺功能。检测包括肺量计检查、体积描记法、痰细胞计数、呼出气一氧化氮(FeNO)、甘露醇气道高反应性、使用强迫震荡技术测量呼吸系统力学以及使用多次呼吸氮气冲洗法测量通气异质性。作为小气道通气异质性的测量指标,衍生出依赖对流通气异质性和依赖弥散通气异质性的参数。如果 ACQ 评分大于或等于 1.5(加量),则加倍 ICS 剂量;如果 ACQ 评分小于 1.5(减量),则四分之一剂量 ICS。使用 Spearman 相关分析、逐步线性回归和受试者工作特征曲线分析,考察基线生理参数与仅症状 5 项 ACQ(deltaACQ-5)变化之间的关系。
ICS 剂量加量(n=20)可改善 ACQ-5 评分(从 1.76 降至 1.16;P=0.04)。基线呼出气一氧化氮分数(r=-0.55;P=0.01)和依赖对流通气异质性(r=-0.64;P=0.002)与 deltaACQ-5 相关,但依赖对流通气异质性是唯一的独立预测因子(r²=0.34;P=0.007)。ICS 剂量减量(n=41)会使 ACQ-5 评分恶化(从 0.46 增至 0.80;P<0.001),其中 29%的患者 deltaACQ-5 大于 0.5。仅基线依赖弥散通气异质性与 deltaACQ-5 相关(r=0.40;P=0.009),并可识别出 deltaACQ-5 大于 0.5 的患者(受试者工作特征曲线下面积为 0.78;P=0.0003)。
通气异质性可预测 ICS 剂量滴定后的症状反应。较小气道功能更差预示着 ICS 剂量加量时症状改善,而剂量减量时则失去症状控制。